Literature DB >> 2293768

Successful treatment of refractory anemia with high-dose methylprednisolone.

T Motoji1, M Teramura, M Takahashi, K Oshimi, M Okada, K Kusakabe, H Mizoguchi.   

Abstract

Five patients with refractory anemia were treated with high-dose methylprednisolone. An immediate and long-lasting hematological improvement without serious side effects was achieved in two of the patients, although chromosomal abnormalities persisted in both. The clinical course and laboratory data of these two patients are described. Restoration of normal hematopoiesis was achieved regardless of the enhancement of colony formation of granulocyte progenitor cells by the simultaneous addition of hydrocortisone in vitro. The same treatment was given to six patients who had refractory anemia with an excess of myeloblasts (RAEB), but no improvement was observed in any of these patients. It appears that high-dose methylprednisolone can be valuable in the treatment of refractory anemia, but is not useful for RAEB.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293768     DOI: 10.1002/ajh.2830330103

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.

Authors:  M Werner; H Maschek; V Kaloutsi; H Choritz; A Georgii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

2.  Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome.

Authors:  Mitsuru Itoh; Kazuhiro Yago; Hideto Shimada; Kaoru Tohyama
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

3.  Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A.

Authors:  Toshiki Yamada; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Michio Sawada; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-10       Impact factor: 4.553

4.  Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.

Authors:  H Maschek; V Kaloutsi; M Rodriguez-Kaiser; M Werner; H Choritz; K Mainzer; M Dietzfelbinger; A Georgii
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

5.  Diagnostic and prognostic values of S-phase fraction and aneuploidy in patients with bone marrow aplasia.

Authors:  Payal Tripathi; Anil Kumar Tripathi; Ashutosh Kumar; Rizwan Ahmad; Anil Kumar Balapure; Achchhe Lal Vishwakerma
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.